Session: Trials in Progress Poster Session
Type: Trials in Progress Poster Session
Time: Monday June 7, 8:00 AM to 12:00 PM
Location: S Hall A2
http://abstract.asco.org/AbstView_74_49960.html
A multicenter dose-finding randomized controlled phase IIb study of the aptamer AS1411 in patients with primary refractory or relapsed AML.
Sub-category: Leukemia
Category: Leukemia, Myelodysplasia, and Transplantation
Meeting: 2010 ASCO Annual Meeting
Citation: J Clin Oncol 28:7s, 2010 (suppl; abstr TPS279)
Abstract No: TPS279
Author(s): R. K. Stuart, A. Wei, I. D. Lewis, E. Estey, F. Erlandsson, G. J. Schiller; Medical University of South Carolina, Charleston, SC; The Alfred Hospital, Melbourne, Australia; Royal Adelaide Hospital, Adelaide, Australia; University of Washington Medical Center, Seattle, WA; Antisoma Research Ltd., London, United Kingdom; University of California, Los Angeles School of Medicine, Los Angeles, CA
Abstract:
Background: Aptamers are small synthetic oligonucleotides that form stable nuclease-resistant 3D structures and bind target proteins with specificity and affinity similar to antibodies. These "chemical antibodies" represent a new class of therapeutics. AS1411 is the first aptamer to enter phase II trials in cancer. The AS1411 aptamer binds nucleolin, which is overexpressed on the surface of cancer cells, and induces apoptosis. A 70-patient randomized controlled phase II trial evaluated AS1411 in combination with cytarabine in patients with relapsed and refractory AML. Patients were treated with AS1411 10 mg/kg/day + cytarabine 3 g/m2/day (AS1411-10), AS1411 40 mg/kg/day + cytarabine 3 g/m2/day (AS1411-40), or cytarabine 3 g/m2/day alone (control). CR+CRp rates were: AS1411-10, 21%; AS1411-40, 19%; control, 5%. The combination was well tolerated. These findings led to the current phase IIb study, which tests the value of a further doubling in the dose of AS1411 against a background of a slightly higher cytarabine dose in less heavily treated AML patients. Methods: 90 patients will be randomized 1:1:1 to 3 arms: AS1411 40 mg/kg/day + cytarabine 4 g/m2/day, AS1411 80 mg/kg/day + cytarabine 4 g/m2/day, or cytarabine 4 g/m2/day alone (control). AS1411 will be administered CI days 1-7, and cytarabine will be administered bid IV days 4-7. Patients aged 18-70 with ECOG 0-2 must have primary refractory AML with > 20% blasts on baseline bone marrow assessment or AML in first relapse with > 5% marrow blasts. Key exclusion criteria are APL, secondary AML, and clinically active CNS leukemia. The primary objective of the study is to compare response rates (CR+CRi) with the three regimens. Secondary objectives are comparisons of duration of remission, disease-free survival and overall survival, hematologic recovery and safety, and assessment of pharmacokinetics. Exploratory pharmacodynamic assessment of the effects of AS1411 will be carried out on bone marrow aspirate and trephine biopsy samples taken before and after treatment. Patients who do not respond to cytarabine alone will be eligible to cross over to receive AS1411 + cytarabine at the investigator's discretion.
Recent ASM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 11:45:24 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 10:06:09 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 10/30/2023 10:30:20 AM
- AVINO ANNOUNCES Q2 2023 PRODUCTION RESULTS • PR Newswire (Canada) • 07/20/2023 10:45:00 AM
- AVINO ANNOUNCES Q2 2023 PRODUCTION RESULTS • PR Newswire (US) • 07/20/2023 10:45:00 AM
- AVINO DRILLS BEST INTERCEPT IN COMPANY HISTORY • PR Newswire (US) • 07/05/2023 10:45:00 AM
- AVINO DRILLS BEST INTERCEPT IN COMPANY HISTORY • PR Newswire (Canada) • 07/05/2023 10:45:00 AM
- AVINO RENEWS US ATM SHARE OFFERING • PR Newswire (Canada) • 06/21/2023 09:24:00 PM
- AVINO RENEWS US ATM SHARE OFFERING • PR Newswire (US) • 06/21/2023 09:24:00 PM
- AVINO REPORTS VOTING RESULTS OF ITS 2023 ANNUAL GENERAL MEETING AND APPOINTS NEW DIRECTOR • PR Newswire (Canada) • 06/20/2023 11:18:00 PM
- AVINO REPORTS VOTING RESULTS OF ITS 2023 ANNUAL GENERAL MEETING AND APPOINTS NEW DIRECTOR • PR Newswire (US) • 06/20/2023 11:18:00 PM
- AVINO VEIN EXTENDED A FURTHER 500 METRES • PR Newswire (US) • 05/23/2023 07:45:00 AM
- AVINO VEIN EXTENDED A FURTHER 500 METRES • PR Newswire (Canada) • 05/23/2023 07:45:00 AM
- Avino Reports Q1 2023 Financial Results; Realizes Numerous Operational Achievements • PR Newswire (US) • 05/10/2023 09:48:00 PM
- Avino Reports Q1 2023 Financial Results; Realizes Numerous Operational Achievements • PR Newswire (Canada) • 05/10/2023 09:48:00 PM
- AVINO SILVER & GOLD MINES LTD. FIRST QUARTER 2023 FINANCIAL RESULTS TO BE RELEASED ON WEDNESDAY, MAY 10, 2023 • PR Newswire (US) • 05/03/2023 10:29:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM